Zidesamtinib
- Generic Name
- Zidesamtinib
Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC (NVL-520-EAP)
- Conditions
- Non Small Cell Lung CancerROS1-positive Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2025-01-28
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Nuvalent Inc.
- Registration Number
- NCT06797362
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, Auvergne-Rhône-Alpes, France
🇳🇱University Medical Center Groningen, Groningen, Netherlands
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Phase 1
Recruiting
- Conditions
- Metastatic Solid TumorLocally Advanced Solid Tumor
- Interventions
- First Posted Date
- 2021-11-12
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Nuvalent Inc.
- Target Recruit Count
- 359
- Registration Number
- NCT05118789
- Locations
- 🇺🇸
UCI Medical Center, Orange, California, United States
🇺🇸Stanford Medicine, Palo Alto, California, United States
🇺🇸UC Davis Comprehensive Cancer Center, Sacramento, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath